1. Britton Chance: The Development of In Vivo MRS Mitchell Schnall MD, PhD

2. Metabolism as a basis for understanding and curing disease

3. Warm Ischemia 4 degrees C

5. 75 second spectrum

7. Exercising in the NMR magnet

9. The Transfer function: “Furthermore, the slope and extent of the linear portion of Fig. 4 are pivotal in the identification of normal and pathological functions of the limb.” Figure 4

10. Assuming ADP control and Michaelis- Menten kinetics assuming a constant pH of 7.1, a temperature of 370C, a 1.0-mM magnesium concentration, and a 5-mM ATP concentration giving Kobs, = 132 (1) and Km ADP = 20 AM (19, 24). Vmax of 52 J/min and a Km of 0.65 ± 0.06.

11. PFK

12. Recovery kinetics as a Biomarker PFK deficient PVD patient

13. Vitamin K 3 Vitamin C

14. Detecting Treatment Response 0 5 10 Min Normal Subject Patient prior to (A) and after (B) therapy

16. 1985

17. BC’s Contribution to MRS Established feasibility to real time measurement of metabolites in perfused organs, intact animal models, and humans Developed a mechanistic approach to interpretation of spectral data for the purpose of clinical diagnostics Developed a strategy of using MRS as a pharmaco-dynamic marker of treatment effect Established the role of PME (choline in the proton spectrum) as an important marker of malignancy Inspired the development of methodology to support further application of MRS – Surface coils – Chemical shift imaging – Rotating frame imaging – Multinuclear spectroscopy – Hadamard spectroscopy – NMR pulse design methodology – Multimodality Optical-MR spectroscopy

18. Brit’s own acknowledgements